

PUTTING PURPOSE INTO ACTION

# WORKING RESPONSIBLY

FY20 SUMMARY



We insist on the highest ethical and quality standards in every part of our business, from our senior leaders to our supply chain. This allows us to deliver safe and effective products, the right way.



**52,000**  
EMPLOYEES ACROSS  
75 COUNTRIES

participated in our Ethics and Integrity Week

**2,000+**  
EMPLOYEES DEDICATED TO  
THE SAFETY AND EFFICACY  
of our clinical trials

**\$2.4b**  
SPENT  
with small and diverse suppliers in the  
United States and Puerto Rico

**65%**  
OF NEW PRODUCTS UNDERWENT  
PREDICTIVE ENGINEERING –  
HELPING REDUCE THE TIME TO  
MARKET FOR VITAL TREATMENTS



**Medtronic**

## IMPACT AT EVERY LEVEL

It's not just our end products that make a difference. We spend billions of dollars in our supply chain, choosing to support small and historically underrepresented businesses. Annually, we undertake a detailed assessment of our impact with diverse suppliers in the U.S. and Puerto Rico:

**\$2.4b**  
PURCHASES

**24,257**  
JOBS  
SUPPORTED

**\$1.4b**  
WAGES AND  
BENEFITS



## PARTNERING FOR IMPACT WITH DIVERSE-OWNED FIRMS



In FY20, our operational headquarters in Minneapolis, Minnesota, spent \$796 million with local suppliers.\* Thirty-one percent of that business went to small and diverse businesses like JIT Energy Services.

Medtronic has partnered with JIT to reduce our environmental impact, ultimately helping us reach our environmental targets for more than a decade. Not only are they members of our community, they're also one of Medtronic's largest Black-owned supplier partners.

"We believe diversity drives better business results," says Medtronic CEO Geoff Martha. "This includes creating a diverse supply chain — one that delivers exceptional quality while also benefiting the patients and physicians we serve and the broader communities in which we operate."

\* We define local being within the state of Minnesota

## PROTECTING PROGRESS

People rely on the rigorous and comprehensive clinical studies that go into testing and launching new products and therapies. The COVID-19 pandemic had a significant impact on clinical trials worldwide. We quickly developed remote monitoring and assessment options that not only help us respond but transform. When we resume in-person engagement, we plan to continue using many of these approaches, as these innovations can help improve efficiency, performance, and quality in a clinical trial setting.

Supply chains were similarly disrupted. We had to continue manufacturing and distributing lifesaving products — especially those that could save the lives of COVID-19 patients. Following announcements of shutdowns, we collaborated with suppliers to operate as essential businesses, establishing safety measures for workers and increasing production of ventilators and other products to meet the growing global need. As a result, patients could continue to receive the medical supplies and devices that are critical to their health.

